One of north India's largest private hospital groups, with a network of cancer units, a standalone cancer centre in Delhi and a large share of India's private-sector oncology trials.
Max Healthcare opened its first centre in Panchsheel Park, Delhi, in 2000 and in June 2025 operated 22 hospitals with more than 5,000 beds, mainly in north India; it is listed on the BSE and NSE and is a NIFTY 50 constituent. A standalone Max Cancer Centre was commissioned in Lajpat Nagar, Delhi, in 2016, and the group's oncology programme (marketed as the Max Institute of Cancer Care) spans surgical, medical, radiation and haemato-oncology, bone marrow transplant, robotic surgery and precision oncology across its network. Max is a frequent site for international registration trials in India.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Max Healthcare, including child institutions. 100 works · 949 citations · 69% open access · 8% clinical trials · 2% reviews.
Shares Robotic & minimally invasive surgery, Comprehensive genomic profiling, Head and neck squamous cell carcinoma, Diffuse large B-cell lymphoma.
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer.
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
Shares Robotic & minimally invasive surgery, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
Shares Robotic & minimally invasive surgery, Comprehensive genomic profiling, Diffuse large B-cell lymphoma, Non-small-cell lung cancer.
Shares Robotic & minimally invasive surgery, Comprehensive genomic profiling, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer.
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Robotic & minimally invasive surgery, CAR-T cell therapy, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.